Skip to search formSkip to main contentSkip to account menu

ombrabulin

Known as: (2S)-2-amino-3-hydroxy-n-(2-methoxy-5-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)phenyl)propanamide 
A synthetic water-soluble analogue of combretastatin A4, derived from the South African willow bush (Combretum caffrum), with potential vascular… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

AC 7700
Microtubule ProcessNCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers
The high mortality associated with oncological diseases is mostly due to tumors in advanced stages, and their management is a… 
Review
2017
Review
2017
The development and use of vascular targeted therapy in ovarian cancer.
2016
2016
Phase 1 study of ombrabulin in combination with cisplatin (CDDP) in Japanese patients with advanced solid tumors.
OBJECTIVE In clinical studies in Western countries, the recommended dose of combination ombrabulin a vascular disrupting agent… 
Highly Cited
2015
Highly Cited
2015
Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo…
2014
2014
Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors
SummaryPurpose Preclinical evidence supports synergy between the vascular disrupting agent ombrabulin and various chemotherapy… 
2014
2014
A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours
Background:The vascular disrupting agent ombrabulin shows synergy with docetaxel in vivo. Recommended phase II doses were… 
2014
2014
An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients…
AbstractPurpose To determine ombrabulin’s maximum tolerated dose and dose recommended for Japanese patients with advanced solid… 
2013
2013
Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors
Purpose: The vascular disrupting agent ombrabulin rapidly reduces tumor blood flow and causes necrosis in vivo. A phase I dose… 
2013
2013
The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models
SummaryTargeting tumor vasculature is an emerging strategy in cancer treatment. Promising results have been shown in preclinical… 
2012
2012
A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors (NCT01193595).
3080 Background: O is a vascular-disrupting agent derived from combretastatin A4-phosphate that induces rapid but transient tumor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)